Toronto-based Xandar Kardian’s Series A round was led by Phoenix Venture Partners, Portfolio Active Aging & Longevity Fund and Taronga Ventures, among others, according to a news release.
Xandar Kardian develops the XK300 autonomous health monitoring solution, which it touts as the world’s first and only commercially available, contact-free, continuous vital sign monitoring system with FDA 510(k) clearance as a Class II medical device.
The contactless solution for vital sign monitoring offers accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers, the company said. Its radar technology can smart-build implementation to provide commercial and public building operators with real-time occupancy measurements…